KRYS
Krystal Biotech Inc

1,732
Loading...
Loading...
News
all
press releases
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·16d ago
News Placeholder
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Zacks·17d ago
News Placeholder
Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·30d ago
News Placeholder
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
Zacks·2mo ago
News Placeholder
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
Zacks·3mo ago
News Placeholder
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Zacks·3mo ago

Latest KRYS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.